Literature DB >> 26336539

Evaluation of defibrillation safety and shock reduction in implantable cardioverter-defibrillator patients with increased time to detection: A randomized SANKS study.

Mahito Noro1, Xin Zhu2, Takahito Takagi1, Naohiko Sahara1, Yuriko Narabayashi1, Hikari Hashimoto1, Naoshi Ito1, Yoshinari Enomoto1, Shingo Kujime1, Tuyoshi Sakai3, Takao Sakata1, Noriko Matushita4, Seiji Fukamizu4, Yoshifumi Okano5, Yoshiaki Anami6, Tomoyuki Tejima6, Kouji Kuroiwa6, Takanori Ikeda5, Harumizu Sakurada4, Kaoru Sugi1.   

Abstract

BACKGROUND: The need for ways to minimize the number of implantable cardioverter-defibrillator (ICD) shocks is increasing owing to the risk of its adverse effects on life expectancy. Studies have shown that a longer detection time for ventricular tachyarrhythmia reduces the safety of therapies, in terms of syncope and mortality, but not substantially in terms of the success rate. We aimed to evaluate the effects of increased number of intervals to detect (NID) VF on the safety of ICD shock therapy and on the reduction of inappropriate shocks.
METHODS: The present study was a prospective, multicenter, randomized, crossover study. Randomized VF induction testing with NID 18/24 or 30/40 was performed to compare the success rate of defibrillation with a 25-J shock and the time to detection. Inappropriate shock episodes were simulated retrospectively to evaluate a possibility of episodes avoidable at NID 24/32 and 30/40.
RESULTS: Thirty-one consecutive patients implanted with an ICD or cardiac resynchronization therapy-defibrillator (CRT-D) were enrolled in this study. The success rate of defibrillation was 100% in both NID groups at the first shock. The time from VF induction to detection showed a significant increase in the NID 30/40 group (6.16±1.29 s vs. 9.00±1.31 s, p<0.001). Among the 120 patients implanted with an ICD or CRT-D, 10 experienced 32 inappropriate shock episodes. The inappropriate shock reduction rate was 53.1% and 62.5% with NID 24/32 and 30/40, respectively.
CONCLUSIONS: The findings of this SANKS study suggest that VF NID 30/40 does not compromise the safety of ICD shock therapy, while decreasing the number of inappropriate shocks.

Entities:  

Keywords:  Detection duration; ICD; Shock therapy; Undersense; Ventricular fibrillation

Year:  2014        PMID: 26336539      PMCID: PMC4554355          DOI: 10.1016/j.joa.2014.08.003

Source DB:  PubMed          Journal:  J Arrhythm        ISSN: 1880-4276


  20 in total

1.  Inappropriate implantable cardioverter-defibrillator shocks: incidence, predictors, and impact on mortality.

Authors:  Johannes B van Rees; C Jan Willem Borleffs; Mihály K de Bie; Theo Stijnen; Lieselot van Erven; Jeroen J Bax; Martin J Schalij
Journal:  J Am Coll Cardiol       Date:  2011-02-01       Impact factor: 24.094

2.  Appropriate and inappropriate ventricular therapies, quality of life, and mortality among primary and secondary prevention implantable cardioverter defibrillator patients: results from the Pacing Fast VT REduces Shock ThErapies (PainFREE Rx II) trial.

Authors:  Michael O Sweeney; Mark S Wathen; Kent Volosin; Ismaile Abdalla; Paul J DeGroot; Mary F Otterness; Alice J Stark
Journal:  Circulation       Date:  2005-05-31       Impact factor: 29.690

3.  The CONNECT (Clinical Evaluation of Remote Notification to Reduce Time to Clinical Decision) trial: the value of wireless remote monitoring with automatic clinician alerts.

Authors:  George H Crossley; Andrew Boyle; Holly Vitense; Yanping Chang; R Hardwin Mead
Journal:  J Am Coll Cardiol       Date:  2011-01-20       Impact factor: 24.094

4.  Lead integrity alert algorithm decreases inappropriate shocks in patients who have Sprint Fidelis pace-sense conductor fractures.

Authors:  Linda M Kallinen; Robert G Hauser; Chuen Tang; Daniel P Melby; Adrian K Almquist; William T Katsiyiannis; Charles C Gornick
Journal:  Heart Rhythm       Date:  2010-05-21       Impact factor: 6.343

5.  Effect of ventricular shock strength on cardiac hemodynamics.

Authors:  T Tokano; D Bach; J Chang; J Davis; J J Souza; A Zivin; B P Knight; R Goyal; K C Man; F Morady; S A Strickberger
Journal:  J Cardiovasc Electrophysiol       Date:  1998-08

6.  Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact.

Authors:  James P Daubert; Wojciech Zareba; David S Cannom; Scott McNitt; Spencer Z Rosero; Paul Wang; Claudio Schuger; Jonathan S Steinberg; Steven L Higgins; David J Wilber; Helmut Klein; Mark L Andrews; W Jackson Hall; Arthur J Moss
Journal:  J Am Coll Cardiol       Date:  2008-04-08       Impact factor: 24.094

7.  Downloadable algorithm to reduce inappropriate shocks caused by fractures of implantable cardioverter-defibrillator leads.

Authors:  Charles D Swerdlow; Bruce D Gunderson; Kevin T Ousdigian; Athula Abeyratne; Robert W Stadler; Jeffrey M Gillberg; Amisha S Patel; Kenneth A Ellenbogen
Journal:  Circulation       Date:  2008-11-03       Impact factor: 29.690

8.  Alterations induced by a single defibrillating shock applied through a chronically implanted catheter electrode.

Authors:  M A Barker-Voelz; J F Van Vleet; W A Tacker; J D Bourland; L A Geddes; M P Schollmeyer
Journal:  J Electrocardiol       Date:  1983-04       Impact factor: 1.438

9.  Prognostic importance of defibrillator shocks in patients with heart failure.

Authors:  Jeanne E Poole; George W Johnson; Anne S Hellkamp; Jill Anderson; David J Callans; Merritt H Raitt; Ramakota K Reddy; Francis E Marchlinski; Raymond Yee; Thomas Guarnieri; Mario Talajic; David J Wilber; Daniel P Fishbein; Douglas L Packer; Daniel B Mark; Kerry L Lee; Gust H Bardy
Journal:  N Engl J Med       Date:  2008-09-04       Impact factor: 91.245

10.  Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study.

Authors:  Bruce L Wilkoff; Brian D Williamson; Richard S Stern; Stephen L Moore; Fei Lu; Sung W Lee; Ulrika M Birgersdotter-Green; Mark S Wathen; Isabelle C Van Gelder; Brooke M Heubner; Mark L Brown; Keith K Holloman
Journal:  J Am Coll Cardiol       Date:  2008-08-12       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.